A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population … (NCT06741111) | Clinical Trial Compass
CompletedNot Applicable
A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up Database
India1,233,970 participantsStarted 2025-01-21
Plain-language summary
The primary objective of this study is to estimate the proportion of people with low/intermediate/high risk of advanced fibrosis in at risk Chinese population based on the European Association for the Study of the Liver (EASL) 2024 care pathway
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female, age above or equal to 18 years on health-check-up visit day
✓. No missing value on sex
✓. Must be part of study population.
✓. People with T2D or \[obesity＋above or equal to 1 cardiometabolic risk factor(s)\] or elevated liver enzymes
✓. Must be part of EASL at risk population
✓. Must be part of study population.
✓. People with 2 or more metabolic risk factors (EASL-MASLD criteria) or T2D or steatosis on any imaging modality or with elevated aminotransferases
✓. Must be part of study population.
Exclusion criteria
✕. Individuals originating from centers with fewer than 100 participants
✕. Missing value of liver stiffness measurement (LSM)
✕. Had an interquartile range/median ratio above or equal to 30% of the measurement of LSM
✕. Missing value on either aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or platelet count (PLT)
✕. Missing value on FPG, TG, HDLc or BP (to define the presence of metabolic risk factors)
What they're measuring
1
The proportion of people with low/intermediate/high risk of advanced fibrosis in EASL at risk population based on EASL 2024 care pathway.
Timeframe: January 1st, 2023, to December 31st, 2023